Allurion Technologies, Inc. (NYSE:ALUR) Accelerates FDA Pathway; Balance Sheet Stabilization Ahead

Recent News

On November 12, 2025, Allurion announced a third-quarter 2025 business update noting passage of FDA pre‑approval inspections with zero observations, acceptance into PMA substantive review for the Allurion Smart Capsule (including a completed Day‑100 meeting), and a transaction to exchange outstanding debt for convertible preferred equity alongside a $5 million private placement; the company also described R&D and manufacturing process validation efforts.

Technical Analysis

Directional indicators show emerging trend strength: ADX at 21.12 indicates an emerging trend rather than a well‑established move, which tempers conviction in directional breakouts or breakdowns.

DI+ sits at 22.42 with a peak‑and‑reversal pattern, which signals bearish directional pressure; DI– at 21.56 shows a dip‑and‑reversal that further aligns with increasing negative directional force. Together these DI readings bias near‑term price momentum toward the downside.

MACD reads -0.02 with a MACD signal of -0.04 and a documented peak‑and‑reversal; the MACD trend profile points to weakening momentum, yet the MACD currently sits above its signal line, producing a bullish crossover that can support a short‑lived bounce within an otherwise fragile momentum regime.

MRO at 13.92 registers positive with a peak‑and‑reversal trend; this implies price sits above the model target and carries downward pressure, increasing the risk that a bounce will give way to renewed selling toward intrinsic anchors used in valuation.

RSI at 42.43 with a peak‑and‑reversal pattern signals faded upside momentum and room for further consolidation or decline before oversold thresholds emerge; this aligns with price trading below short‑ and long‑term averages.

Price sits at $1.50, below the 20‑day average ($1.60), the 50‑day ($1.70) and the 200‑day average ($2.33), with the 12‑day EMA ($1.58) showing a peak‑and‑reversal. The Ichimoku cloud (Senkou A $1.88, Senkou B $1.96) lies above price, indicating resistance overhead. Low recent volume (11,778 versus a 10‑day average of 45,428) weakens conviction in directional moves, while a 42‑day beta of 3.43 signals elevated short‑term volatility relative to the broader market. These factors imply any technical rebound may meet structural resistance and limited conviction without stronger volume or a sustained MACD/RSI shift.

Fundamental Analysis

Revenue fell materially: total revenue stands at $2,658,000 with year‑over‑year revenue decline of 60.77% and quarter‑over‑quarter revenue decline of 45.90%, reflecting sharp top‑line contraction.

Profitability remains deeply negative. Net income equals -$11,884,000 and operating income equals -$9,630,000. EBIT margin registers -446.76%, versus an industry peer mean of 11.15% and industry peer median of 16.79%, signaling a large divergence from peer profitability norms; EBIT margin improved QoQ by 62.46% and improved YoY by 168.36%, but absolute margins remain heavily negative.

Cash and leverage present a mixed picture. Cash and short‑term investments total $6,136,000 while total debt equals $33,393,000, producing net debt of $26,104,000 and enterprise value of $43,368,532 against a market capitalization of $16,111,532. Those capital structure figures correspond with an enterprise‑to‑revenue multiple of 16.32x and a price‑to‑sales ratio of 6.06x, which underpin WMDST’s determination that the current valuation reads as over‑valued given revenue scale and net debt exposure.

Cash flow metrics show operating cash flow of -$6,544,000 and free cash flow of -$6,544,000, with a free‑cash‑flow yield of -40.62% (negative). Cash conversion cycle remains extended at about 210 days, with days inventory outstanding at ~385 days and days payables outstanding at ~343 days, indicating working capital tied up across operations.

Earnings metrics present improvement in reported EPS versus expectations: reported EPS equals -$1.18 versus an estimate of -$2.45, producing an EPS surprise of +$1.27 and an EPS surprise ratio of 51.84%. Forward EPS estimates sit at -$0.12 with a forward PE near -22.96. Book value per share reads negative at -$10.67693, creating a negative price‑to‑book ratio (-0.19x) relative to an industry peer mean price‑to‑book of 3.77x and median of 2.41x.

Operational efficiency metrics remain challenged but show pockets of improvement: asset turnover stands at 0.1148 with small QoQ and YoY increases; gross margin remains relatively healthy at 49.06% but gross profit ($1,304,000) cannot offset high operating expense levels. Return on equity reads 14.33% while return on assets sits at -51.32%, reflecting negative leverage from the balance sheet structure and low asset base.

Overall valuation context: WMDST values the stock as over‑valued. The valuation reflects an enterprise‑to‑revenue multiple of 16.32x, high net debt relative to cash, and deeply negative operating margins despite recent QoQ and YoY margin improvements; the company’s ability to convert regulatory progress into sustainable revenue scale and improved cash generation represents the primary path toward closing this valuation gap.

Six-Week Outlook

Regulatory catalysts dominate the short window: the substantive PMA review and recent financing actions reduce immediate binary risk but leave the share susceptible to newsflow and sentiment. Technicals bias toward consolidation to the downside given DI+/DI– and MACD momentum patterns, while the MACD crossover and low RSI allow for intermittent relief rallies. Elevated short‑term volatility (42‑day beta ~3.43) and thin trading volume increase the likelihood of sharp, transient moves rather than gradual trends. Monitor for confirmed MACD and RSI renewals above key short‑term averages and sustained volume to validate any near‑term bullish shift; absent those, the path of least resistance favors continued consolidation under major moving averages with downside pressure supported by the MRO signal and elevated net debt metrics.

About Allurion Technologies, Inc.

Allurion Technologies (NYSE:ALUR) focuses on addressing obesity with innovative weight loss solutions. Based in Natick, Massachusetts, the company offers the Allurion Program, which includes the Allurion Balloon, a swallowable, non-surgical intragastric balloon designed to assist in weight loss. This balloon provides a procedure-free option for individuals seeking to reduce weight without invasive surgery. In addition to the balloon, Allurion Technologies provides a comprehensive weight management platform. The Allurion Virtual Care Suite integrates AI-driven remote patient monitoring to facilitate seamless tracking of health metrics and progress. This platform supports users with a proprietary behavior change program, encouraging sustainable lifestyle changes. Secure messaging and video telehealth services offer personalized guidance and care from healthcare professionals, enhancing user support. Allurion Technologies aims to make effective weight loss more accessible and achievable. By leveraging advanced technology and offering comprehensive support, the company seeks to improve the quality of life for individuals struggling with obesity.

© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.